MAXIMISE results in axial manifestations of PsA. SEC met primary phase 3b ASAS 20 endpoint after inadequate NSAID response. https://t.co/e1j03KOo1K #ACR19 @RheumNow abs#2880 https://t.co/UtSDJGAW2G
Links:
Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis …
http://ow.ly/1jPl50x3Cuf
Nov-13-2019
